If You Invested in QT Imaging Holdings, Inc. (QTI)
Looking for the current price? See the QTI quote & overviewWhat $1,000 or $10,000 in QTI Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jan 28, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $357 -64% |
| $10,000 | — | — | — | $3,573 -64% |
Based on real historical closing prices adjusted for stock splits, without dividends, through the latest market close. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results. We start QTI on Jan 28, 2026 because the prices we hold from before that date cannot be compared with the later ones, and a return measured across the two would be wrong.
Custom Calculation
Choose your own date and amount for QTI$1,000 Investment Over Time
QTI vs S&P 500Year-by-Year Returns
QTI annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026Jan 28, 2026 to Oct 30, 2026 | $5.99 | $2.14 | -64.3% | -64.3% |
About QT Imaging Holdings, Inc.
Healthcare · NASDAQ
QT Imaging Holdings Overview
QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company headquartered in Novato, California. The company is engaged in the research, development and commercialization of body imaging systems that use low-frequency sound waves. Its stated focus is breast health management through radiation-free imaging technology.
QT Imaging's business centers on medical imaging for the detection, diagnosis and treatment of disease. The company's public materials describe its technology as a way to produce breast images without radiation, breast compression or contrast injection. That focus places QTI in the medical device and diagnostic imaging field, with an emphasis on breast imaging rather than a broad hospital equipment portfolio.
Breast Acoustic CT Imaging
The company's principal named system is the Breast Acoustic CT™ Scanner. QT Imaging states that the scanner produces true three-dimensional, radiation-free and compression-free images of the breast using low-energy sound waves. The system is described as providing quantitative imaging biomarkers derived from the intrinsic acoustic properties of breast tissue.
QT Imaging has stated that the Breast Acoustic CT Scanner is FDA-cleared as an adjunctive breast imaging device for women 18 years of age and older. The company also describes the platform as designed to provide accurate imaging for dense breasts without radiation, compression or contrast injection. These attributes are central to how the company explains its role in breast health management.
QT Imaging's products include QTviewer. Together with the Breast Acoustic CT Scanner, this gives the company a product identity tied to imaging hardware and image viewing rather than pharmaceuticals, laboratory testing or surgical devices.
Technology Platform
QT Imaging describes its breast imaging platform as quantitative and operator-independent. The company has also referred to development work involving reconstruction, quantitative imaging algorithms, clinical workflow and the QTI Precision Pathway™ cloud platform. Public company communications have described a pathway toward AI-enabled biomarkers and precision diagnostics, while tying those efforts to breast imaging and quantitative analysis.
The company's technology description is based on acoustic properties of tissue, not ionizing radiation. In public releases, QT Imaging has emphasized that its scanner uses low-energy sound waves and avoids compression. The company has also stated that its system can support quantitative biomarkers, which means the imaging output is described in measurable terms rather than only as visual images.
Commercialization and Market Access
QT Imaging is a commercial-stage medical device company in the sense that its public materials discuss scanner shipments, revenue from operations and commercialization activity. The company has described its commercial approach as combining distribution partnerships with direct U.S. commercial and business development capabilities. It has also identified NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA, Inc., as part of an existing distribution arrangement.
The company has described its strategy as evolving from a distributor-led sales model toward an integrated commercial model. In its own description, that model is intended to support direct customer engagement, strategic account development, clinical education and market development. These statements should be read as the company's stated commercial framework, not as a guarantee of adoption or financial performance.
Regulatory and Quality Context
Medical device companies depend on regulatory status and quality systems because products used in patient care are subject to oversight. QT Imaging has disclosed that the Breast Acoustic CT Scanner is FDA-cleared as an adjunctive breast imaging device for adult women. The company has also announced that its first routine inspection by the U.S. Food and Drug Administration ended with zero Form 483 observations, and that the inspection reviewed its Quality Management System and related processes.
QT Imaging has also announced regulatory registration from the Israeli Ministry of Health for its scanner, based on its existing U.S. FDA clearance and applicable Israeli regulatory requirements. This disclosure supports the company's stated focus on commercialization of its breast imaging system beyond its U.S. regulatory foundation.
Corporate Profile
QT Imaging Holdings is incorporated in Delaware and trades on Nasdaq under the symbol QTI. SEC filings identify the company as an emerging growth company. Its recent public filings include quarterly reports on Form 10-Q, current reports on Form 8-K and a definitive proxy statement for stockholder voting matters.
As a public medical device issuer, QTI's filings contain information about results of operations, equity incentive plans, executive compensation actions, stockholder meeting matters, financing activity and accounting items related to its business combination and earnout liabilities. These filings are especially relevant because the company is operating in a regulated medical device category where commercialization, capital needs, regulatory status and product development are central to investor analysis.
Associated Private-to-Public Equity Entities
The issuer record also identifies several named Private-to-Public Equity, or PPE, entities with stated acquisition purposes:
- GigInternational1 was formed for the purpose of acquiring a company in TMT, aerospace and defense, mobility and semiconductor industries, with emphasis on the EMEA market.
- GIG2 was formed for the purpose of acquiring a company in the TMT industry.
- GIG3 was formed for the purpose of acquiring a company in the TMT industry.
- GIG4 was formed for the purpose of acquiring a company in the TMT and sustainable industries.
Those PPE entities are distinct from QT Imaging's present medical device operating identity. QTI's company-specific public description, news and filings identify QT Imaging Holdings as a medical device company focused on imaging systems, breast health management and commercialization of its Breast Acoustic CT technology.
Similar Stocks
See how related companies performed
Frequently Asked Questions
QT Imaging Holdings, Inc. investment returns
How much would $1,000 invested in QT Imaging Holdings, Inc. be worth today?
Limited historical data is available for QTI. The prices we can compare start on 2026-01-28.
Has QT Imaging Holdings, Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare QTI performance over available time periods.
For informational and educational purposes only, not investment advice.